SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial have?
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial has 36 citations in the OpenAlex counts ScholarIQ stores.
When was SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial published?
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial has 2023 year in the ScholarIQ index.
What is the open-access status of SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial?
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial has closed oa status in the ScholarIQ index.
What is the DOI of SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial?
The DOI for SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial is on the source record.
What is the PMID of SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial?
The PMID for SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial is on the source record.
What is the OpenAlex record for SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial?
The OpenAlex for SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial is on the source record.